ArticleISRN oncology2013
Diabetes and risk of cancer.
Article in ISRN oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Does cancer risk increase with HbA1c, independent of diabetes?British journal of cancer · 2014Pooled it
- Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis.European journal of epidemiology · 2013Pooled it
- Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes.Journal of diabetes investigation · 2019Trial
- Metformin in gastrointestinal cancers and inflammatory bowel disease: Unraveling its mechanisms and therapeutic applications.iScience · 2026Review
- Diabetes and cancer: therapeutic implications.Cardio-oncology (London, England) · 2026Review
- Sitagliptin Potentiates the Anticancer Activity of Doxorubicin Through ROS-Driven Apoptosis and MMP/TIMP Regulation in HeLa Cells.Pharmaceutics · 2025Article
- The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review.Journal of clinical medicine · 2025Review
- Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024Review
- Incident Cancer Risk in Patients with Incident Type 2 Diabetes Mellitus in Hungary (Part 1).Cancers · 2024Article
- Prevalence and impact of endocrine disorders in advanced metastatic cancer patients undergoing cancer-directed therapy: A prospective observational study.Cancer reports (Hoboken, N.J.) · 2024Observational
- AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2024Article
- Article
- Periodontal Disease and Other Adverse Health Outcomes Share Risk Factors, including Dietary Factors and Vitamin D Status.Nutrients · 2023Review
- A Role for Advanced Glycation End Products in Molecular Ageing.International journal of molecular sciences · 2023Review
- Sex-Based Differences in Clinical Profile and Complications among Individuals with Type 2 Diabetes Seen at a Private Tertiary Diabetes Care Centre in India.Healthcare (Basel, Switzerland) · 2023Article
- Diabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening.Science advances · 2022Article
- Cancer, diabetes, survival and glycemic control: a large multisite analysis.Future science OA · 2022Article
- Metabolic risk factors of ovarian cancer: a review.JBRA assisted reproduction · 2022Review
- Evaluating the Relationship between Diabetes and Cancer in a Cohort.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Association Between Diabetes and the Risk of Kidney Cancer: Systematic Review and Meta-Analysis.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes and cancer represent two complex, diverse, chronic, and potentially fatal diseases. Cancer is the second leading cause of death, while diabetes is the seventh leading cause of death with the latter still likely underreported. There is a growing body of evidence published in recent years that suggest substantial increase in cancer incidence in diabetic patients. The worldwide prevalence of diabetes was estimated to rise from 171 million in 2000 to 366 million in 2030. About 26.9% of all people over 65 have diabetes and 60% have cancer. Overall, 8-18% of cancer patients have diabetes. In the context of epidemiology, the burden of both diseases, small association between diabetes and cancer will be clinically relevant and should translate into significant consequences for future health care solutions. This paper summarizes most of the epidemiological association studies between diabetes and cancer including studies relating to the general all-site increase of malignancies in diabetes and elevated organ-specific cancer rate in diabetes as comorbidity. Additionally, we have discussed the possible pathophysiological mechanisms that likely may be involved in promoting carcinogenesis in diabetes and the potential of different antidiabetic therapies to influence cancer incidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.